de Diego Damiá Alfredo, Vega Chicote José María
Servicio de Neumología, Hospital Universitario La Fe, Valencia, España.
Arch Bronconeumol. 2011 Apr;47 Suppl 2:27-31. doi: 10.1016/S0300-2896(11)70018-7.
Bronchial asthma is a chronic inflammatory disease that affects both the large-caliber airways and the smaller-caliber bronchioles. In the last few years, a major therapeutic advance has been made with the development of new systems of inhalation solutions, which produce extra-fine particles, achieving better lung deposition throughout the airways and reducing oropharyngeal deposition. These formulations have improved the effectiveness of bronchodilation and particularly the antiinflammatory effect. The use of long-acting b2-adrenergic steroids in extra-fine formulation, whether alone or in combinations of fixed doses, improves drug distribution throughout the bronchial tree, enhancing the therapeutic effect with lower doses of drugs. Leukotriene receptor antagonists have shown their effect on the small airways in asthmatic patients, both in studies of pulmonary resistance and pulmonary volumes and in imaging studies.
支气管哮喘是一种慢性炎症性疾病，会影响大口径气道和小口径细支气管。在过去几年中，随着新型吸入溶液系统的开发取得了重大治疗进展，该系统可产生超细微颗粒，在整个气道中实现更好的肺部沉积，并减少口咽沉积。这些制剂提高了支气管扩张的有效性，尤其是抗炎效果。长效β2-肾上腺素能类固醇以超细微制剂形式使用，无论是单独使用还是以固定剂量组合使用，都能改善药物在整个支气管树中的分布，以较低剂量的药物增强治疗效果。白三烯受体拮抗剂在哮喘患者的小气道中已显示出其作用，无论是在肺阻力和肺容积研究中还是在影像学研究中。
